Table 2.
Patient characteristics (1–16 Norway, 17–32 Japan)
| Number | Gender Follow-up (months) |
Aged (years) |
Primary tumor Interval to reRT (months) |
Secondary diagnosis | Treated region | Dose per fraction (Gy), number of fractions | Technique | Spinal cord Dmax | Spinal cord D0.1cc | EQD2 Dmax (Gy) | EQD2 D0.1cc (Gy) | Cumulative EQD2 Dmax (Gy) | Cumulative EQD2 D0.1cc (Gy) | Risk score (points) Risk group |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | 53 | C54.2 | C79.5 | Th11/12 | 3 × 13 | 3‑D conformal | 101% | 101% | 49.53 | 49.53 | 81.26 | 81.26 | 5 |
| 9 | – | 16 | – | Th11/12 | 3 × 10 | 2‑D dose reconstructed | 90% | 90% | 31.73 | 31.73 | – | – | Intermediate | |
| 2 | Male | 65 | C18.9 | C79.5 | Th12-L2 | 3.5 × 10 | 2‑D dose reconstructed | 87% | 87% | 38.41 | 38.41 | 68.49 | 68.49 | 2 |
| 11 | – | 14 | – | Th12-L2 | 3 × 10 | 2‑D dose reconstructed | 87% | 87% | 30.08 | 30.08 | – | – | Low | |
| 3 | Male | 54 | C64.9 | C79.5 | Th4‑6 | 3 × 10 | 2‑D dose reconstructed | 89% | 89% | 31.17 | 31.17 | 62.34 | 62.34 | 1 |
| 48 | – | 18 | – | Th4‑6 | 3 × 10 | 2‑D dose reconstructed | 89% | 89% | 31.17 | 31.17 | – | – | Low | |
| 4 | Female | 67 | C25.9 | C77.2 | Paraaortic nodes (Th 12) | 2.5 × 15 | 2‑D dose reconstructed | 98% | 98% | 40.88 | 40.88 | 73.16 | 73.16 | 3 |
| 6 | – | 10 | – | Paravertebral (Th12) | 3 × 10 | 3‑D conformal | 91% | 91% | 32.28 | 32.28 | – | – | Low | |
| 5 | Female | 53 | C34.9 | – | Mediastinum (Th12) | 2.8 × 15 | 3‑D conformal | 93% | 93% | 44.96 | 44.96 | 78.96 | 78.96 | 4 |
| 6 | – | 6 | C79.3 | Th12-S2 | 4 × 7 | 2‑D dose reconstructed | 88% | 88% | 34.00 | 34.00 | – | – | Intermediate | |
| 6 | Female | 64 | C34.9 | – | Right lung (Th5-8) | 8.5 × 2 | 2‑D dose reconstructed | 95% | 95% | 40.68 | 40.68 | 61.12 | 61.12 | 1 |
| 11 | – | 9 | – | Right lung (Th5-8) | 2.8 × 15 | 3‑D conformal | 55% | 55% | 20.44 | 20.44 | – | – | Low | |
| 7 | Male | 55 | C34.9 | C79.5 | C5‑7 | 2 × 15 + SIB 0.7 × 15 | 3‑D conformal | 97%a | 97% | 28.66 | 28.66 | 61.50 | 61.50 | 1 |
| 24 | – | 8 | – | C5‑7 | 3 × 10 | 2‑D dose reconstructed | 92% | 92% | 32.84 | 32.84 | – | – | Low | |
| 8 | Female | 61 | C04.9 | C79.5 | C2‑5 | 8 × 1 | 2‑D dose reconstructed | 99% | 99% | 19.64 | 19.64 | 64.95 | 64.95 | 1 |
| 9 | – | 26 | – | Head & neck (C2-3) | 2 × 35 | 3‑D conformal | 99%b | 99% | 45.31 | 45.31 | – | – | Low | |
| 9 | Male | 50 | C15.5 | C77.1 | Mediastinum | 3 × 10 | 3‑D conformal | 85% | 85% | 29.01 | 29.01 | 63.72 | 63.72 | 1 |
| 14 | – | 32 | – | Esophagus (Th6-7) | 2 × 25 | 3‑D conformal | 78% | 78% | 34.71 | 34.71 | – | – | Low | |
| 10 | Male | 81 | C34.9 | C79.5 | Th5‑8 | 2.8 × 7 | 2‑D dose reconstructed | 92% | 92% | 20.63 | 20.63 | 72.64 | 72.64 | 7.5 |
| 50 | – | 20 | – | Mediastinum | 2.8 × 15 | 3‑D conformal | 102% | 102% | 52.01 | 52.01 | – | – | High | |
| 11 | Female | 54 | C50.9 | C79.5 | Th11-L1 | 4 × 5 | 2‑D dose reconstructed | 101% | 101% | 30.50 | 30.50 | 67.40 | 67.40 | 2 |
| 10 | – | 13 | – | Th11-L1 | 3 × 10 | 2‑D dose reconstructed | 99% | 99% | 36.90 | 36.90 | – | – | Low | |
| 12 | Female | 68 | C90.0 | – | Th6-10 | 2.8 × 10 | 2‑D dose reconstructed | 96% | 96% | 31.50 | 31.50 | 67.81 | 67.81 | 2 |
| 8 | – | 12 | – | Th8-10 | 3 × 10 | 2‑D dose reconstructed | 98% | 98% | 36.31 | 36.31 | – | – | Low | |
| 13 | Male | 58 | C34.9 | C77.1 | Mediastinum (Th7-8) | 2 × 15 + boost 2.5 × 3 | 3‑D conformal | 97%c | 97% | 33.15 | 33.15 | 68.77 | 68.77 | 2 |
| 7 | – | 8 | – | Mediastinum | 2.8 × 15 | 3‑D conformal | 80% | 80% | 35.62 | 35.62 | – | – | Low | |
| 14 | Female | 55 | C50.9 | C79.5 | C6-Th4 | 3 × 10 | 2‑D dose reconstructed | 98% | 98% | 36.31 | 36.31 | 74.41 | 74.41 | 3 |
| 57 | – | 27 | – | C7-Th5 | 3 × 10 | 2‑D dose reconstructed | 101% | 101% | 38.10 | 38.10 | – | – | Low | |
| 15 | Male | 82 | C90.0 | – | C7-Th2 | 3 × 10 | 3‑D conformal | 101% | 101% | 38.10 | 38.10 | 73.82 | 73.82 | 3 |
| 16 | – | 50 | – | C6-Th3 | 3 × 10 | 2‑D dose reconstructed | 97% | 97% | 35.72 | 35.72 | – | – | Low | |
| 16 | Male | 73 | C34.9 | – | Mediastinum | 3 × 9 | 3‑D conformal | 98% | 98% | 32.68 | 32.68 | 82.76 | 82.76 | 5 |
| 6 | – | 13 | – | Mediastinum | 1.5 × 2 (BID) x15 + boost 2 × 4 | 3‑D conformal | Different | Different | 50.08 | 50.08 | – | – | Intermediate | |
| 17 | Male | 60 | C64.9 | C79.5 | C1‑3 | 2 × 20 | 3‑D conformal | 99% | 98% | 39.40 | 38.81 | 108.86 | 89.21 | 14.5 for Dmax, 6 for D0.1cc |
| 61 | – | 29 | – | C2‑3 | 4.5 × 10 | IMRT | 97% | 80% | 69.46 | 50.40 | – | – | High (Dmax), intermediate | |
| 18 | Male | 60 | C73.9 | C79.5 | Th2‑6 | 3 × 12 | Single beam | 112% | 112% | 54.03 | 54.03 | 104.43 | 95.53 | 13.5 for Dmax, 12.5 for D0.1cc |
| 18 | – | 97 | – | Th3‑5 | 4.5 × 10 | IMRT | 80% | 71% | 50.40 | 41.50 | – | – | High | |
| 19 | Female | 65 | C34.9 | C79.5 | Th8 | 2.5 × 16 | 3‑D conformal | 105% | 105% | 48.56 | 48.56 | 80.15 | 74.21 | 5 for Dmax, 3 for D0.1cc |
| 15 | – | 13 | – | Th8 | 3 × 15 | IMRT | 69% | 60% | 31.59 | 25.65 | – | – | Intermediate (Dmax), low | |
| 20 | Male | 82 | C34.9 | C79.5 | Th7‑9 | 3 × 10 | 3‑D conformal | 110% | 109% | 43.73 | 43.08 | 91.86 | 82.61 | 7 for Dmax, 5 for D0.1cc |
| 35 | – | 14 | – | Th6‑7 | 5 × 10 | IMRT | 70% | 62% | 48.13 | 39.53 | – | – | High (Dmax), intermediate | |
| 21 | Female | 47 | C22.0 | C79.5 | Th7‑9 | 3 × 10 | 3‑D conformal | 103% | 102% | 39.32 | 38.71 | 92.31 | 81.41 | 11.5 for Dmax, 5 for D0.1cc |
| 90 | – | 18 | – | Th8‑9 | 4 × 13 | IMRT | 79% | 69% | 52.99 | 42.70 | – | – | High (Dmax), intermediate | |
| 22 | Male | 74 | C22.0 | C79.5 | Skull base-C4 | 3 × 10 | 3‑D conformal | 99% | 99% | 36.90 | 36.90 | 87.68 | 80.88 | 6 for Dmax, 5 for D0.1cc |
| 7 | – | 7 | – | C2 | 3 × 20 | IMRT | 78% | 71% | 50.78 | 43.98 | – | – | Intermediate | |
| 23 | Male | 67 | C22.0 | C79.5 | Th12 | 2 × 20 | 3‑D conformal | 61% | 55% | 19.64 | 17.05 | 77.17 | 72.15 | 8.5 for Dmax, 7.5 for D0.1cc |
| 8 | – | 12 | – | Th12 | 5 × 10 | IMRT | 78% | 76% | 57.53 | 55.10 | – | – | High | |
| 24 | Male | 82 | C22.0 | C79.5 | C7-Th2 | 3 × 10 | Single beam | 103% | 103% | 39.32 | 39.32 | 82.37 | 77.83 | 5 for Dmax, 4 for D0.1cc |
| 12 | – | 20 | – | Th1‑3 | 3 × 20 | IMRT | 70% | 65% | 43.05 | 38.51 | – | – | Intermediate | |
| 25 | Male | 64 | C34.9 | C79.5 | Th9-10 | 3 × 10 | Single beam | 105% | 105% | 40.56 | 40.56 | 114.79 | 95.62 | 15.5 for Dmax, 12.5 for D0.1cc |
| 8 | – | 70 | – | Th8-10 | 4 × 15 | IMRT | 89% | 74% | 74.23 | 55.06 | – | – | High | |
| 26 | Male | 43 | C34.9 | – | Mediastinum | 2 × 30 | 3‑D conformal | 68% | 67% | 34.27 | 33.57 | 97.65 | 86.29 | 12.5 for Dmax, 10.5 for D0.1cc |
| 20 | – | 38 | C79.5 | Th2 | 4.2 × 13 | IMRT | 84% | 75% | 63.38 | 52.72 | – | – | High | |
| 27 | Male | 72 | C22.0 | C79.5 | Th2‑3 | 2 × 23 | 3‑D conformal | 105% | 104% | 49.51 | 48.80 | 95.39 | 88.20 | 8 for Dmax, 6 for D0.1cc |
| 12 | – | 35 | – | Th2 | 3 × 20 | IMRT | 73% | 66% | 45.88 | 39.40 | – | – | High (Dmax), intermediate | |
| 28 | Male | 57 | C64.9 | C79.5 | C2-Th2 | 3 × 10 | 3‑D conformal | 102% | 102% | 38.71 | 38.71 | 87.50 | 79.92 | 6 for Dmax, 4 for D0.1cc |
| 47 | – | 64 | – | Th2 | 3 × 20 | IMRT | 76% | 68% | 48.79 | 41.21 | – | – | Intermediate | |
| 29 | Male | 58 | C15.9 | C79.5 | C6-Th1 | 3 × 10 | 3‑D conformal | 97% | 97% | 35.72 | 35.72 | 89.48 | 73.71 | 10.5 for Dmax, 3 for D0.1cc |
| 9 | – | 9 | – | C6-Th1 | 3.5 × 16 | IMRT | 80% | 64% | 53.76 | 37.99 | – | – | High (Dmax), low | |
| 30 | Male | 57 | C64.9 | C79.5 | C2-Th2 | 3 × 10 | 3‑D conformal | 106% | 105% | 41.18 | 40.56 | 103.3 | 88.67 | 13.5 for Dmax, 6 for D0.1cc |
| 41 | – | 70 | – | C2 | 3.2 × 19 | IMRT | 86% | 73% | 62.12 | 48.11 | – | – | High (Dmax), intermediate | |
| 31 | Female | 46 | C20.9 | C79.5 | Th2‑9 | 2.5 × 15 | 3‑D conformal | 104% | 104% | 44.85 | 44.85 | 92.96 | 86.71 | 7 for Dmax, 6 for D0.1cc |
| 9 | – | 6 | – | Th3‑8 | 4 × 14 | IMRT | 71% | 65% | 48.11 | 41.86 | – | – | High (Dmax), intermediate | |
| 32 | Male | 69 | C22.1 | C79.5 | C2 | 2 × 20 | 3‑D conformal | 102% | 101% | 41.21 | 40.60 | 89.01 | 83.46 | 6 for Dmax, 5 for D0.1cc |
| 26 | – | 7 | – | C2 | 3.3 × 18 | IMRT | 73% | 68% | 47.80 | 42.86 | – | – | Intermediate |
ReRT re-irradiation, SIB simultaneous integrated boost, BID two fractions per day with 6 h interval, EQD2 equivalent dose in 2‑Gy fractions, IMRT intensity-modulated radiotherapy, Dmax maximum dose
aSIB did not contribute, based on 2 Gy x 15
bonly the first 23 fractions contributed
cboost contributed less (1.67 Gy per fraction)
dat start of re-irradiation